DOXORUBICIN , Rinatabart Sesutecan, PACLITAXEL clinical trials

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

This study is testing a new drug, Rinatabart Sesutecan (Rina-S), for people with advanced endometrial cancer. It compares Rina-S to standard treatments to see if it works better at slowing down or stopping the cancer's growth and helping people live longer after previous treatments.